Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2444193 | 0.99 | LMNA (0.62) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL13426202 | 0.86 | ALDH1A1 (0.61) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL12438415 | 0.86 | KDM4E (0.63) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL20037664 | 0.85 | ALDH1A1 (0.57) | ALDH1A1POLBSMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL1231713 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL1134961 | 0.84 | LMNA (0.59) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL12438389 | 0.84 | LMNA (0.59) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL12438405 | 0.84 | ALDH1A1 (0.59) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL1134988 | 0.84 | LMNA (0.59) | ALDH1A1LMNASLC22A2SLC22A1TSHR | |
| SCHEMBL29369961 | 0.84 | LMNA (0.59) | ALDH1A1LMNASLC22A2SLC22A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046789-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INST NAT SANTE RECH MED (FR) | 2012-09-05 | — | — | EP | claimed |
| EP-2046789-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INST NAT SANTE RECH MED (FR) | 2012-09-05 | — | — | EP | disclosed |
| EP-2363399-A1 | Labelled analogues of halobenzamides as radiopharmaceuticals | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-09-07 | — | — | EP | disclosed |
| US-20110178396-A1 | Nicotinamide Derivatives | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2011-07-21 | — | — | US | disclosed |
| US-20110178396-A1 | Nicotinamide Derivatives | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2011-07-21 | — | — | US | disclosed |
| US-20110178396-A1 | Nicotinamide Derivatives | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2011-07-21 | — | — | US | disclosed |
| EP-2285778-A1 | NICOTINAMIDE DERIVATIVES | CRC for Biomedical Imaging Development Ltd (AU) | 2011-02-23 | — | — | EP | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| WO-2009129573-A1 | NICOTINAMIDE DERIVATIVES | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129573-A1 | NICOTINAMIDE DERIVATIVES | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008012782-A2 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | HRH3, H1-3, HRH4 | ALDH1A1 794/4885LMNA 2206/4885SLC22A2 1058/4885 |
| US-20110178396-A1 | Nicotinamide Derivatives | NAMPT, NNT, NNMT | ALDH1A1 883/4885LMNA 2345/4885SLC22A2 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.